一般而言,作者对CAR-T毒性的管理决策在老年和年轻患者之间没有显著差异(参见Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy.Blood. 2023;141(20):2430-2442)。我们允许使用托珠单抗治疗持续性1级CRS,并且更有可能在老年患者中使用托珠单抗,如果老年患者进展到2级...
例如,需区分DLBCL与形态相似的其他淋巴瘤亚型,如浆母细胞淋巴瘤、T细胞淋巴瘤等,以及与反应性淋巴组织增生等良性病变的鉴别。 王教授结合实际病例展示了诊断过程中的陷阱与挑战,强调病理医生在诊断时需综合考虑多种因素,必要时借助分子检...
2025年3月25日16:00-17:30,由中国临床肿瘤学会(CSCO)与良医汇共同主办的【How we treat·江苏省人民经验】系列直播会议拉开帷幕。首期直播主题为“CNS受累DLBCL患者的诊疗探索:治疗现状与优化策略”,由江苏省人民医院徐卫教授领衔,江...
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, yet curable, malignancy, but older patients are at higher risk of relapsed disease because they may not be eligible for full-intensity frontline chemoimmunotherapy or have comorbidities that limit standard treatments. Recent years have brought ...
How I treat unique and difficult-to-manage cases of CAR T-cell therapy–associated neurotoxicity Blood, 141 (20) (2023), pp. 2443-2451 View PDFView articleView in ScopusGoogle Scholar Cited by (120) Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed...
How we treat Richter syndrome Richter syndrome (RS) is defined as the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most commonly diffuse large B-cel... SA Parikh,NE Kay,TD Shanafelt - 《Blood》 被引量: 103发表: 2014年 How we treat Richter syndrome ...
Allogeneic HSCT is indicated in several different types of lymphomas such as diffuse large B cell lymphoma (DLBCL) with relapse after autologous HSCT or in case of chemorefractory disease. Allo-HSCT following the failure of ibrutinib treatment may be an option in mantle cell lymphoma (MCL) and ...
HSCT treat- ment can be divided into separate phases that start with the harvest of the stem cells and passing through the conditioning, aplasia and engraftment until the recovery of the haemato- poietic functions. HSCT is indicated in many diseases, and these indications depend on numerous ...
弥漫大B细胞淋巴瘤(DLBCL)是一类具有高度异质性的常见非霍奇金淋巴瘤(NHL)亚型。近年来,随着肿瘤免疫疗法与基因测序技术的发展,淋巴瘤的诊疗手段日新月异,为进一步提高我国临床医师对DLBCL的诊断及治疗水平,由中国临床肿瘤学会(CSCO)...
李维教授:在双抗没有正式上市之前,对于此类患者可能会选择稍微更强的诱导方案。如果一线疗效欠佳,仍然伴有突变,并且未转化的情况下,可能会选择细胞免疫治疗。此外,基于弥漫大B细胞淋巴瘤(DLBCL)的治疗经验,双抗联合靶向药物、双抗联合...